´ëÇѽÅÀåÇÐȸ APCN & KSN 2024 4ÀÏÂ÷ : 2024-06-16 |
|
´ëÇѽÅÀåÇÐȸ APCN & KSN 2024 4ÀÏÂ÷ : 2024-06-16 ±³À°ÁÖÁ¦ : APCN & KSN 2024 4ÀÏÂ÷ ÁÖÃÖ±â°ü : ´ëÇѽÅÀåÇÐȸ À̸ÞÀÏ : ksn@ksn.or.kr ±³À°Á¾·ù : ³»°ú Âü¼®¿¹»óÀÎ : 2000¸í Áö¿ª : ¼¿ïƯº°½Ã ¼¼ºÎ¼ö°·á : 250,000¿ø ºñ°í ¡áȸ¿ø: »çÀü(200,000)/ÇöÀå(250,000) ¡áºñȸ¿ø: »çÀü(250,000)/ ÇöÀå(250,000) ¡áPhysician in training/Nurse/Paramedics/Allied Health: »çÀü(100,000)/ ÇöÀå(125,000) *Student, ¸¸65¼¼ ÀÌ»ó ȸ¿ø: ¸éÁ¦
±³À°½Ã°£ 06¿ù 16ÀÏ Room 1 08:30~09:00 Can HIF Stabilizers Replace ESA in Patients with Hemodialysis? Pros vs. Cons ±èÁöÀº(°í·Á´ëÇб³ ±¸·Îº´¿ø) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 1 09:00~09:30 CKD-MBD Management: About the New Phosphate Binder Ȳ¼±´ö(ÀÎÇϴ뺴¿ø) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 1 09:30~10:00 Strategies for Achieving High Volume HDF Á¶¾ÆÁø(ÇѸ²´ëÇб³ °³²¼º½Éº´¿ø) ÈÞ½Ä 06¿ù 16ÀÏ 10:00~10:30 Break () ±³À°½Ã°£ 06¿ù 16ÀÏ Room 1 10:30~11:00 Monitoring and Surveillance in Hemodialysis Access ±èÇü´ö(°¡Å縯´ëÇб³ ÀºÆò¼º¸ðº´¿ø) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 1 11:00~11:30 Vascular Ultrasound ±¸»ó°Ç(»ý¸í¼±ÀÇ¿ø) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 1 11:30~12:00 Application of Ultrasound in Nephrology Other than Vascular Ultrasound ±èÀºÁ¤(ÇѸ²´ëÇб³ µ¿Åº¼º½Éº´¿ø) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 2 08:30~09:00 Ç÷¾×Åõ¼®¸·ÀÇ ±¸Á¶¿Í ¼º´É ¹× °¡Àå ÀûÇÕÇÑ Åõ¼®¸·ÀÇ ¼±ÅÃÀº ÀÌÀåÇÑ(ºÐ´çÁ¦»ýº´¿ø) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 2 09:00~09:30 Current Evidence of Anticoagulation Therapy in Hemodialysis Patient ¹ÚÇýÀÎ(ÇѸ²´ëÇб³ °³²¼º½Éº´¿ø) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 2 09:30~10:00 Ç÷¾×Åõ¼®À» À§ÇÑ ¼öÁú°ü¸® ¹× Åõ¼®Àåºñ À¯Áö¸¦ À§ÇÑ ¼Òµ¶Áöħ ±èÀ¯°æ(¹Ú½ºÅÍ) ÈÞ½Ä 06¿ù 16ÀÏ 10:00~10:30 Break () ±³À°½Ã°£ 06¿ù 16ÀÏ Room 2 10:30~11:00 Åõ¼®È¯ÀÚÀÇ °¡·Á¿òÁõ °ü¸® Á¤º¸¿µ(ÇѸ²´ëÇб³ °³²¼º½Éº´¿ø) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 2 11:00~11:30 ÀÚµ¿º¹¸·Åõ¼®(APD)ÀÇ ÀÌÇØ¿Í °£È£ °û¹ÌÇý(¼¿ï¾Æ»êº´¿ø) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 2 11:30~12:00 Ç÷¾×Åõ¼® ÁßȯÀÚ °ü¸® ÀÌÇö¿µ(»ï¼º¼¿ïº´¿ø) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 3 08:30~08:50 °í·É ȯÀÚÀÇ Åõ¼® À¯º¸¿Í °ü·ÃÇÑ À±¸®Àû ±Ç°í¾È ¼±ÀοÀ(¿¹¼öº´¿ø) Çʼö ±³À°½Ã°£ 06¿ù 16ÀÏ Room 3 08:50~09:10 °í·É ȯÀÚÀÇ Åõ¼® Áß´Ü°ú °ü·ÃÇÑ À±¸®Àû ±Ç°í¾È ±è¼¸°(¾ç»êºÎ»ê´ëÇб³º´¿ø) Çʼö ±³À°½Ã°£ 06¿ù 16ÀÏ Room 3 09:10~09:30 °í·É ȯÀÚÀÇ Åõ¼® À¯º¸¿Í Áß´Ü°ú °ü·ÃÇÑ ÇØ¿Ü ±Ç°í¾È¿¡ ´ëÇÑ À±¸®Àû Á¢±Ù ¹× ºñ±³ ºÐ¼® ÃÖÀº°æ(°æºÏ´ëÇб³ ÀÇ°ú´ëÇÐ) Çʼö ±³À°½Ã°£ 06¿ù 16ÀÏ Room 3 09:30~10:00 °í·É ȯÀÚÀÇ Åõ¼® À¯º¸¿Í Áß´Ü ±Ç°í¾È¿¡ ´ëÇÑ À±¸®Àû °í·Á»çÇ× ÀÌÀº¿µ(ºÎ»ê °¡Å縯´ëÇб³) Çʼö ±³À°½Ã°£ 06¿ù 16ÀÏ Room 3 10:00~10:30 °í·É ȯÀÚÀÇ Åõ¼® À¯º¸¿Í Áß´Ü ¶§ º¸Á¸ÄáÆÏ°ü¸®ÀÇ À±¸®Àû °í·Á»çÇ× ¹× Çʿ伺 ½Å¼ºÁØ(µ¿±¹´ëÇб³ Àϻ꺴¿ø) Çʼö ±³À°½Ã°£ 06¿ù 16ÀÏ Room 3 10:30~10:50 ADPKD Treatment and New European Guidelines on Tolvaptan Vladimir Tesar(Charles University) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 3 10:50~11:10 Genetic- and Kidney Disease-related Asymptomatic Hyperuricemial Mechanisms and Clinical Implications Stephanie Steiger(LMU Hospital) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 3 11:10~11:30 Modeling of Genetic Kidney Disease and Development of New Therapeutics Using Patient Derived Induced Pluripotent Stem Cells Á¤º´ÇÏ(°¡Å縯´ëÇб³ ¼¿ï¼º¸ðº´¿ø) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 3 11:30~11:50 Current Treatment Status of Fabry Nephropathy in Korea ÀÌÇÏÁ¤(Harvard Medical School) Åä·Ð 06¿ù 16ÀÏ Room 3 11:50~12:00 Q&A All Speaker() ±³À°½Ã°£ 06¿ù 16ÀÏ Room 4 08:30~09:50 KRCP: The Current and the Future Hakmmok Kang, Kent Doi, Ming-Zhi Zhang, Çã¼±(Vanderbilt University, The University of Tokyo Graduate School of Medicine, ÇѸ²´ëÇб³) Åä·Ð 06¿ù 16ÀÏ Room 4 09:50~10:00 Q&A All Speaker() ÈÞ½Ä 06¿ù 16ÀÏ 10:00~10:30 Break () ±³À°½Ã°£ 06¿ù 16ÀÏ Room 4 10:30~11:00 Emergency Preparedness and Kidney Disease - Sharing Know-Hows of ISN RDPWG Ali Abu-Alfa(American University of Beirut) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 4 11:00~11:30 Dietary Plan for Korean Renal Hemodialysis Patients in a Disaster Emergency Situation ÀåÀ¯¹Ì(¿ï»ê´ëÇб³ ½ÄÇ°¿µ¾çÇаú) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 4 11:30~12:00 Emergency Medical System for Disaster Response in Hospitals (Centered on Artificial Kidney Units) ÃÖ¿íÁø(¿ï»ê´ëÇб³º´¿ø ÀÀ±ÞÀÇÇаú) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 5 08:30~08:50 Conservative Kidney Management & Palliativa Care: Dialysis Withhold and Withdrawal ½Å¼ºÁØ(µ¿±¹´ëÇб³ Àϻ꺴¿ø) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 5 08:50~09:10 Strategies to Increase Kidney Transplantation Mai-Szu Wu(Taipei Medical University) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 5 09:10~09:30 Patient Selection and Prescription of Hemodiafiltration Ikuto Masakane(Yabuki Hospital) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 5 09:30~09:50 PD-first Policy in Hong Kong: Pros and Cons Philip Kam-Tao Li(Prince of Wales Hospital) Åä·Ð 06¿ù 16ÀÏ Room 5 09:50~10:00 Q&A All Speaker() ÈÞ½Ä 06¿ù 16ÀÏ 10:00~10:30 Break () ±³À°½Ã°£ 06¿ù 16ÀÏ Room 5 10:30~10:50 HD VA Endovascular Thrombectomy, Tips for Beginners ³ª±â·®(Ãæ³²´ëÇб³º´¿ø) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 5 10:50~11:10 Ultrasound of Kidneys and Bladder: Clinical Case Scenarios Vandana Niyyar(Emory University School of Medicine) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 5 11:10~11:30 Native Fistula Should Remain the First Choice of Vascular Access for Elderlies Hideki Kawanishi(Tsuchiya General Hospital) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 5 11:30~11:50 Examination of Vascular Access: Best Practices and Tools Jernej Pajek(University Medical Center Ljubljana) Åä·Ð 06¿ù 16ÀÏ Room 5 11:50~12:00 Q&A All Speaker() ±³À°½Ã°£ 06¿ù 16ÀÏ Room 6 09:00~09:30 Differences Between OPO Structures and Roles and Their Advantages and Disadvantages: (US vs Spain vs Australia) Stefan Tullius(Harvard Medical School) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 6 09:30~10:00 Key Foundations for OPO Success I: Ethics, Compliance, Data Integrity, and Healthcare Collaboration Ghazali Ahmad(National Heart Institute) ±³À°½Ã°£ 06¿ù 16ÀÏ Room 6 10:00~10:30 Key Foundations for OPO Success II: Comprehensive Training for Coordinators Dong Van He(Vietnam National Coordinating Center for Human Organ Transplantation (VNHOT)) ÈÞ½Ä 06¿ù 16ÀÏ 10:30~11:00 Break () ±³À°½Ã°£ 06¿ù 16ÀÏ Room 6 11:00~11:30 Key Foundations for OPO Success III: Cultural Awareness and Public Engagement Yingyos Avihingsanon(Chulalongkorn University) Åä·Ð 06¿ù 16ÀÏ Room 6 11:30~12:00 Panel Discussion: Country Experience Cons and Pros in OPO All Speaker()
|
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù. |
|